Therapeutic targets of the TNF superfamily /
Tumor necrosis factor (TNF) superfamily is a rapidly growing family of cytokines that interacts with a corresponding superfamily of receptors. Ligand-receptor interactions of this superfamily are involved in numerous biological processes ranging from hematopoiesis to pleiotropic cellular responses,...
| Other Authors: | |
|---|---|
| Format: | Book |
| Language: | English |
| Published: |
New York, N.Y. : Austin, Tex. :
Springer Science+Business Media ; Landes Bioscience,
©2009
New York, N.Y. : Austin, Tex. : c2009 |
| Series: | Advances in experimental medicine and biology ;
v. 647 |
| Subjects: |
| LEADER | 09586nam a22009134a 4500 | ||
|---|---|---|---|
| 001 | a352c9b6-95c1-44c8-a68e-4db8766e4546 | ||
| 005 | 20240729000000.0 | ||
| 008 | 081027s2009 nyua ob 001 0 eng c | ||
| 015 | |a GBA8C6123 |2 bnb | ||
| 016 | 7 | |a 014794006 |2 Uk | |
| 016 | 7 | |a 101487676 |2 DNLM | |
| 016 | 7 | |z 014794006 |2 Uk | |
| 016 | 7 | |z 101487676 |2 DNLM | |
| 019 | |a 489218430 |a 496123262 | ||
| 020 | |a 0387895191 | ||
| 020 | |a 0387895205 | ||
| 020 | |a 9780387895192 | ||
| 020 | |a 9780387895208 | ||
| 035 | |a (ICU)8890392 | ||
| 035 | |a (OCoLC)451643109 |z (OCoLC)489218430 |z (OCoLC)496123262 |z (OCoLC)607988209 |z (OCoLC)646833698 |z (OCoLC)880316310 |z (OCoLC)985054383 |z (OCoLC)1005789106 |z (OCoLC)1044227188 |z (OCoLC)1056320820 |z (OCoLC)1087017200 |z (OCoLC)1162705669 |z (OCoLC)1204068826 |z (OCoLC)1256380867 | ||
| 035 | |a (OCoLC)451643109 |z (OCoLC)489218430 |z (OCoLC)496123262 | ||
| 037 | |a 978-0-387-89519-2 |b Springer |n http://www.springerlink.com | ||
| 040 | |a COO |b eng |c COO |d WTU |d GW5XE |d N$T |d UBY |d PUL |d IDEBK |d CEF |d OCLCQ | ||
| 040 | |a COO |b eng |e pn |c COO |d WTU |d GW5XE |d N$T |d UBY |d PUL |d IDEBK |d CEF |d OCLCQ |d BEDGE |d OCLCQ |d STF |d E7B |d OCLCO |d OCLCQ |d CDX |d YDXCP |d SLY |d OCLCQ |d VT2 |d Z5A |d OCLCO |d OCLCQ |d UAB |d OCLCO |d ESU |d OCLCO |d OCLCA |d OCLCF |d U3W |d WYU |d LHU |d YOU |d OCLCO |d OCLCQ |d W2U |d CNTRU |d AUD |d OCLCA |d LQU |d OCLCA |d INARC |d EUN |d OCLCO |d DCT |d OCLCQ |d OCLCO |d CSt | ||
| 042 | |a pcc | ||
| 049 | |a CGUA | ||
| 049 | |a MAIN | ||
| 050 | 4 | |a QR185.8.T84 |b T44 2009 | |
| 060 | 4 | |a QW 568 |b T3985 2009 | |
| 060 | 4 | |a W1 |b AD559 v.647 2009 | |
| 072 | 7 | |a MED |x 044000 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.07/9 |2 22 |
| 084 | |a R979. 1 |2 clc | ||
| 090 | |a QR185.8.T84 |b T44 2009 | ||
| 245 | 0 | 0 | |a Therapeutic targets of the TNF superfamily / |c edited by Iqbal S. Grewal |
| 260 | |a New York, N.Y. : |b Springer Science+Business Media ; |a Austin, Tex. : |b Landes Bioscience, |c ©2009 | ||
| 260 | |a New York, N.Y. : |b Springer Science+Business Media ; |a Austin, Tex. : |b Landes Bioscience, |c c2009 | ||
| 300 | |a 1 online resource (xvii, 220 p.) : |b ill. (some col.) | ||
| 300 | |a 1 online resource (xvii, 220 pages) : |b illustrations (some color) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file | ||
| 347 | |b PDF | ||
| 490 | 1 | |a Advances in experimental medicine and biology ; |v v. 647 | |
| 504 | |a Includes bibliographical references and index | ||
| 505 | 0 | |a GITR : a modulator of immune response and inflammation / Giuseppe Nocentini and Carlo Riccardi -- Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases / Ezogelin Oflazoglu, Iqbal S. Grewal, and Hans Peter Gerber -- Tumor necrosis factor receptor superfamily member 21 : TNFR-related death receptor-6, DR6 / Robert Benschop, Tao Wei, and Songqing Na -- TRAIL and other TRAIL receptor agonists as novel cancer therapeutics / Christina Falschlehner ... [et al.] -- Therapeutic potential of VEGI/TL1A in autoimmunity and cancer / Gautam Sethi, Bokyung Sung and Bharat B. Aggarwal | |
| 505 | 0 | |a GITR : a modulator of immune response and inflammation / Giuseppe Nocentini and Carlo Riccardi -- Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases / Ezogelin Oflazoglu, Iqbal S. Grewal, and Hans Peter Gerber -- Tumor necrosis factor receptor superfamily member 21 : TNFR-related death receptor-6, DR6 / Robert Benschop, Tao Wei, and Songqing Na -- TRAIL and other TRAIL receptor agonists as novel cancer therapeutics / Christina Falschlehner [and others] -- Therapeutic potential of VEGI/TL1A in autoimmunity and cancer / Gautam Sethi, Bokyung Sung and Bharat B. Aggarwal | |
| 505 | 0 | |a Overview of TNF superfamily : a chest full of potential therapeutic targets / Iqbal S. Grewal -- Therapeutic interventions targeting CD40L (CD154) and CD40 : the opportunities and challenges / Che-Leung Law and Iqbal S. Grewal -- Targeting TNF for treatment of cancer and autoimmunity / Gautam Sethi ... [et al.] -- Targeting of BAFF and APRIL for autoimmunity and oncology / Maureen C. Ryan and Iqbal S. Grewal -- The role of FASL and FAS in health and disease / Martin Ehrenschwender and Harald Wajant -- OX40 (CD134) and OX40L / Michael J. Gough and Andrew D. Weinberg -- Targeting CD70 for human therapeutic use / Tamar Boursalian ... [et al.] -- 4-1BB as a therapeutic target for human disease / Seung-Woo Lee and Michael Croft -- Rank(L) as a key target for controlling bone loss / Andreas Leibbrandt and Josef M. Penninger -- Targeting the light-HVEM pathway / Carl F. Ware | |
| 505 | 0 | |a Overview of TNF superfamily : a chest full of potential therapeutic targets / Iqbal S. Grewal -- Therapeutic interventions targeting CD40L (CD154) and CD40 : the opportunities and challenges / Che-Leung Law and Iqbal S. Grewal -- Targeting TNF for treatment of cancer and autoimmunity / Gautam Sethi [and others] -- Targeting of BAFF and APRIL for autoimmunity and oncology / Maureen C. Ryan and Iqbal S. Grewal -- The role of FASL and FAS in health and disease / Martin Ehrenschwender and Harald Wajant -- OX40 (CD134) and OX40L / Michael J. Gough and Andrew D. Weinberg -- Targeting CD70 for human therapeutic use / Tamar Boursalian [and others] -- 4-1BB as a therapeutic target for human disease / Seung-Woo Lee and Michael Croft -- Rank(L) as a key target for controlling bone loss / Andreas Leibbrandt and Josef M. Penninger -- Targeting the light-HVEM pathway / Carl F. Ware | |
| 520 | |a Tumor necrosis factor (TNF) superfamily is a rapidly growing family of cytokines that interacts with a corresponding superfamily of receptors. Ligand-receptor interactions of this superfamily are involved in numerous biological processes ranging from hematopoiesis to pleiotropic cellular responses, including activation, proliferation, differentiation, and apoptosis. The particular response depends on the receptor the cell type, and the concurrent signals received by the cell. Worldwide interest in the TNF field surged dramatically early in 1984 with the cloning and defining of the profound cellular effects of the first member of this family, TNFa. Subsequently, the major influence of TNFa on the development and functioning of the immune system was established. Today, over 20 human TNF ligands and their more than 30 corresponding receptors have been identified. Few receptors still remain orphans. What has emerged over the years is that most TNF ligands bind to one distinct receptor and some of the TNF ligands are able to bind to multiple TNF receptors, explaining to some extent the apparent disparity in the number of TNF receptors and ligands. Yet, in spite of some redundancy in TNF ligand/receptor interactions, it is clear that in vivo spatial, temporal, and indeed cell- and tissue-specific expression of both ligands and their receptors are important factors in determining the precise nature of cellular physiological and pathological processes they control. Therapeutic Targets of the TNF Superfamily presents the state-of-the art account on the role of TNF superfamily members in the pathogenesis and their use in current intervention of cancers and autoimmune disease. This text will be highly valuable for investigators to understand the disease processes regulated by TNF superfamily members and to develop effective therapeutics. A view into the future, inspired by the comprehensive work presented in this volume, predicts that researchers studying TNF superfamily membe rs will continue to make rapid progress in identifying relevant components to the disease process and new therapeutic strategies to target many human diseases including cancers, autoimmune disease and others | ||
| 596 | |a 22 | ||
| 650 | 0 | |a Tumor necrosis factor |x Agonists |x Therapeutic use | |
| 650 | 0 | |a Tumor necrosis factor | |
| 650 | 7 | |a Biomédecine |2 eclas | |
| 650 | 7 | |a MEDICAL |x Immunology |2 bisacsh | |
| 650 | 7 | |a Sciences de la vie |2 eclas | |
| 650 | 7 | |a Tumor necrosis factor |2 fast | |
| 650 | 0 | 7 | |a Autoimmune Diseases |x drug therapy |2 cct |
| 650 | 0 | 7 | |a Inflammation |x drug therapy |2 cct |
| 650 | 0 | 7 | |a Neoplasms |x drug therapy |2 cct |
| 650 | 0 | 7 | |a Receptors, Tumor Necrosis Factor |x therapeutic use |2 cct |
| 650 | 0 | 7 | |a Tumor Necrosis Factors |x therapeutic use |2 cct |
| 650 | 0 | 7 | |a Tumor necrosis factor |2 cct |
| 650 | 0 | 7 | |a Tumor necrosis factor |x Agonists |x Therapeutic use |2 cct |
| 650 | 1 | 2 | |a Tumor Necrosis Factors |x therapeutic use |
| 650 | 2 | 2 | |a Autoimmune Diseases |x drug therapy |
| 650 | 2 | 2 | |a Inflammation |x drug therapy |
| 650 | 2 | 2 | |a Neoplasms |x drug therapy |
| 650 | 2 | 2 | |a Receptors, Tumor Necrosis Factor |x therapeutic use |
| 655 | 4 | |a Electronic books | |
| 700 | 1 | |a Grewal, Iqbal S |1 http://viaf.org/viaf/41324499 | |
| 700 | 1 | |a Grewal, Iqbal S | |
| 776 | 0 | 8 | |i Print version: |t Therapeutic targets of the TNF superfamily |z 9780387895192 |w (OCoLC)265657867 |
| 776 | 0 | 8 | |i Print version: |t Therapeutic targets of the TNF superfamily |z 9780387895192 |w (OCoLC)265657867 |
| 830 | 0 | |a Advances in experimental medicine and biology ; |v v. 647 | |
| 999 | 1 | 0 | |i a352c9b6-95c1-44c8-a68e-4db8766e4546 |l a9110261 |s US-CST |m therapeutic_targets_of_the_tnf_superfamily_________________________________2009_______sprina___________________________________________________________________________e |
| 999 | 1 | 0 | |i a352c9b6-95c1-44c8-a68e-4db8766e4546 |l 8890392 |s US-ICU |m therapeutic_targets_of_the_tnf_superfamily_________________________________2009_______sprina___________________________________________________________________________e |
| 999 | 1 | 1 | |l a9110261 |s ISIL:US-CST |t BKS |a SUL INTERNET |b 9110261-1001 |c INTERNET RESOURCE |d ASIS |x SUL |y 9110261-1001 |p UNLOANABLE |